President Clinton Unveils National AIDS Policy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 2
Volume 6
Issue 2

WASHINGTON--President Clin-ton calls his new national AIDS strategy an important milestone in the history of efforts to end the pandemic that has killed more than 343,000 Americans since 1981. "In the 15 years of this epidemic, we have never had such a unified strategy," the President said. "These goals will guide our work in the coming term and, more specifically, in the coming year."

WASHINGTON--President Clin-ton calls his new national AIDS strategyan important milestone in the history of efforts to end the pandemic thathas killed more than 343,000 Americans since 1981. "In the 15 yearsof this epidemic, we have never had such a unified strategy," thePresident said. "These goals will guide our work in the coming termand, more specifically, in the coming year."

Six General Goals of the National AIDS Strategy

The new policy was drafted by the White House's Office of National AIDSPolicy after consultation with a number of federal agencies, health andmedical groups, religious organizations, and AIDS advocates.

"The development of a national AIDS strategy is a historic undertaking,"said Patricia S. Fleming, director of the AIDS office. She emphasized thebreadth of the new policy, which involves all federal departments and agenciesengaged in HIV-related work; reaches out to communities and the privatesector; and identifies areas where the federal government should focusits efforts.

"The national AIDS strategy provides a foundation for the continuingpublic-private partnerships that are essential to our success in endingthis epidemic," Ms. Fleming added.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content